secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-10-10T23:59:59+00:00
Accession:  0001213900-23-081265
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics receives FDA IND clearance for Phase 1b/2a study of briquilimab in chronic spontaneous urticaria
--------------------------------------------------------------------------------

- FDA cleared IND for Phase 1b/2a repeat dose study of subcutaneous briquilimab in CSU patients.
- First patient expected by end of 2023; early data from initial cohorts by mid-2024.
- Separate CIndU proof-of-concept study to start Q1 2024 with initial data by year-end 2024.
- Study enrolls ~40 patients across 6 cohorts; primary endpoints safety/tolerability, secondary efficacy/PK.
- Targets CSU patients ineligible for or refractory to omalizumab, a high unmet need population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023081265/0001213900-23-081265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023081265/ea186487-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-081265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer